CD276 and small cell lung carcinoma: In a study comparing B7 family ligand expression in SCLC samples, B7-H3 was found to be the most expressed in this group with expression in 64.9% of the SCLC samples tested compared to 7.3% for PD-L1 expression, demonstrating the value of investigating B7-H3 as a therapeutic target for SCLC [61].